DE2610886C2 - - Google Patents

Info

Publication number
DE2610886C2
DE2610886C2 DE2610886A DE2610886A DE2610886C2 DE 2610886 C2 DE2610886 C2 DE 2610886C2 DE 2610886 A DE2610886 A DE 2610886A DE 2610886 A DE2610886 A DE 2610886A DE 2610886 C2 DE2610886 C2 DE 2610886C2
Authority
DE
Germany
Prior art keywords
compound
general formula
group
preparation
compounds according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2610886A
Other languages
German (de)
English (en)
Other versions
DE2610886A1 (de
Inventor
Hendricus Bernardus Antonius Utrecht Nl Welle
Volkert Weesp Nl Claassen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duphar International Research BV
Original Assignee
Duphar International Research BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar International Research BV filed Critical Duphar International Research BV
Publication of DE2610886A1 publication Critical patent/DE2610886A1/de
Application granted granted Critical
Publication of DE2610886C2 publication Critical patent/DE2610886C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19762610886 1975-03-20 1976-03-16 Verbindungen mit antidepressiver wirkung Granted DE2610886A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7503310A NL7503310A (nl) 1975-03-20 1975-03-20 Verbindingen met antidepressieve werking.

Publications (2)

Publication Number Publication Date
DE2610886A1 DE2610886A1 (de) 1976-10-07
DE2610886C2 true DE2610886C2 (esLanguage) 1987-09-24

Family

ID=19823424

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19762610886 Granted DE2610886A1 (de) 1975-03-20 1976-03-16 Verbindungen mit antidepressiver wirkung

Country Status (27)

Country Link
US (1) US4085225A (esLanguage)
JP (1) JPS6026776B2 (esLanguage)
AR (2) AR211011A1 (esLanguage)
AT (1) AT340895B (esLanguage)
AU (1) AU505358B2 (esLanguage)
BE (1) BE839744A (esLanguage)
CA (1) CA1076142A (esLanguage)
CH (4) CH626057A5 (esLanguage)
DD (1) DD128332A5 (esLanguage)
DE (1) DE2610886A1 (esLanguage)
DK (1) DK144942C (esLanguage)
ES (1) ES446192A1 (esLanguage)
FI (1) FI61875C (esLanguage)
FR (1) FR2304336A1 (esLanguage)
GB (1) GB1535226A (esLanguage)
GR (1) GR60052B (esLanguage)
HU (1) HU171030B (esLanguage)
IE (1) IE43768B1 (esLanguage)
IL (1) IL49238A (esLanguage)
IT (1) IT1063064B (esLanguage)
MX (1) MX9203723A (esLanguage)
NL (1) NL7503310A (esLanguage)
PL (3) PL100614B1 (esLanguage)
SE (1) SE410312B (esLanguage)
SU (3) SU635867A3 (esLanguage)
YU (1) YU39345B (esLanguage)
ZA (1) ZA761434B (esLanguage)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1110460B (it) * 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
US5665756A (en) * 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
WO1997006792A1 (en) * 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response
IN182588B (esLanguage) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IN186677B (esLanguage) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
JP2003531169A (ja) * 2000-04-24 2003-10-21 アリックス セラピューティクス うつ病治療のための材料と方法
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
CA2462903C (en) * 2001-10-12 2011-09-20 Serenix Pharmaceuticals, Llc Beta-lactamyl vasopressin v1a antagonists
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
DE602004024317D1 (de) 2003-09-12 2010-01-07 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
DK1691811T3 (da) 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
KR20070004036A (ko) * 2004-04-29 2007-01-05 키스톤 리테이닝 월 시스템스, 아이엔씨 벽, 옹벽 및 그 외 유사한 것을 위한 베니어
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006102283A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
PE20061298A1 (es) 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
JP2008538581A (ja) * 2005-04-22 2008-10-30 ワイス ｛［（２ｒ）−７−（２，６−ジクロロフェニル）−５−フルオロ−２，３−ジヒドロ−１−ベンゾフラン−２−イル］メチル｝アミン塩酸塩の結晶形態
AU2006269231A1 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
EP1910346B1 (en) * 2005-07-19 2019-02-27 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonist
BRPI0613611A2 (pt) * 2005-07-22 2011-01-18 Myriad Genetics Inc formulações de alta concentração de fármaco e formas de dosagens
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CN101410112A (zh) * 2006-03-24 2009-04-15 惠氏公司 治疗抑郁症的新治疗组合
JP4615470B2 (ja) * 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ME02437B (me) 2009-10-23 2016-09-20 Janssen Pharmaceutica Nv Disupstituirani oktahidropirolo[3,4-c]piroli kao modulatori oreksin receptora
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
CN107007596A (zh) 2010-07-01 2017-08-04 阿泽凡药物公司 用于治疗创伤后应激障碍的方法
PH12013501900A1 (en) 2011-03-17 2017-08-23 Lupin Ltd Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
WO2014178064A2 (en) * 2013-04-03 2014-11-06 Zcl Chemicals Limited "an improved process for the preparation of fluvoxamine maleate"
CN106456578B (zh) 2014-02-07 2020-02-18 匈牙利科学院大学及其他机构附属研究所 Sigma-1受体激动剂化合物的用途
WO2015148962A1 (en) 2014-03-28 2015-10-01 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
IL288321B2 (en) 2016-03-10 2025-08-01 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
ES2926179T3 (es) 2016-11-24 2022-10-24 Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag Utilización de composiciones para la conservación de órganos/tejidos
JP2020534274A (ja) 2017-09-15 2020-11-26 アゼヴァン ファーマシューティカルズ，インコーポレイテッド 脳損傷を治療するための組成物及び方法
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes

Also Published As

Publication number Publication date
CH629184A5 (de) 1982-04-15
SU620206A3 (ru) 1978-08-15
JPS6026776B2 (ja) 1985-06-25
GR60052B (en) 1978-04-04
SU645559A3 (ru) 1979-01-30
FR2304336A1 (fr) 1976-10-15
FI61875C (fi) 1982-10-11
SE410312B (sv) 1979-10-08
AU1214776A (en) 1977-09-22
MX9203723A (es) 1992-07-01
HU171030B (hu) 1977-10-28
AR211011A1 (es) 1977-10-14
FI760699A7 (esLanguage) 1976-09-21
ZA761434B (en) 1977-10-26
AU505358B2 (en) 1979-11-15
DK115976A (da) 1976-09-21
IT1063064B (it) 1985-02-11
YU39345B (en) 1984-10-31
BE839744A (fr) 1976-09-20
PL100052B1 (pl) 1978-08-31
GB1535226A (en) 1978-12-13
JPS51125345A (en) 1976-11-01
DD128332A5 (de) 1977-11-09
ATA195476A (de) 1977-05-15
DK144942B (da) 1982-07-12
AR211153A1 (es) 1977-10-31
DK144942C (da) 1982-12-06
PL100614B1 (pl) 1978-10-31
IE43768L (en) 1976-09-20
CH629761A5 (de) 1982-05-14
CH626057A5 (esLanguage) 1981-10-30
FR2304336B1 (esLanguage) 1979-09-28
IE43768B1 (en) 1981-05-20
AT340895B (de) 1978-01-10
IL49238A (en) 1978-08-31
ES446192A1 (es) 1977-10-01
NL7503310A (nl) 1976-09-22
CH629477A5 (de) 1982-04-30
PL101951B1 (pl) 1979-02-28
FI61875B (fi) 1982-06-30
SU635867A3 (ru) 1978-11-30
CA1076142A (en) 1980-04-22
DE2610886A1 (de) 1976-10-07
SE7603341L (sv) 1976-09-21
YU71476A (en) 1982-10-31
US4085225A (en) 1978-04-18
IL49238A0 (en) 1976-05-31

Similar Documents

Publication Publication Date Title
DE2610886C2 (esLanguage)
DE2434911C2 (de) Phenyläthylamin-Derivate und pharmazeutische Zusammensetzungen
DD141520A5 (de) Verfahren zur herstellung neuer derivate von 4-amino-5-alkylsulfonyl-ortho-anisamiden
DE2634288B2 (esLanguage)
DE3329628C2 (esLanguage)
DE3002367A1 (de) 2-substituierte trans-5-aryl-2,3,4,4a,5, 9b-hexahydro-1h-pyrido eckige klammer auf 4,3-b eckige klammer zu indole
DE2305092C2 (esLanguage)
DE2044172C3 (de) Pyrrolderivate, ein Verfahren zu ihrer Herstellung und Arzneimittel
DE3320394A1 (de) Optisch aktive n-arylierte oxazolidinon-(2)-derivate, deren verwendung als spezifische und reversible inhibitoren von monoaminooxydase des b-typs sowie verfahren zu deren herstellung
EP0096279B1 (de) N-(2-Methoxyethyl)-noroxymorphon, dessen Säureadditionssalze, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
DE2609437C2 (esLanguage)
DE2611118C2 (esLanguage)
DE2609862C2 (esLanguage)
DE1915230B2 (de) Hydroxyphenylalkylaminderivate, verfahren zu deren herstellung und arzneimittel auf deren basis
DE2610679C2 (de) Sulfinylgruppenhaltige Oximätherderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
DE2610302A1 (de) Antidepressive verbindungen
DE2615129A1 (de) Tripeptide, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE2421549A1 (de) Naphthalinderivate, verfahren zu ihrer herstellung und arzneimittel
DE2034588B2 (de) ej-Dimethoxy^-benzylisochinoline, Verfahren zu ihrer Herstellung und Arzneimittel
AT282593B (de) Verfahren zur herstellung von neuem racemischem oder optisch aktivem (1-2'-nitrilophenoxy)-2-hydroxy-3-isopropylaminopropan und dessen salzen
AT262289B (de) Verfahren zur Herstellung von neuen Acridanderivaten und ihren Additionssalzen mit anorganischen und organischen Säuren
EP0413302A1 (de) Neue 1,3-Oxazine
DE1518334A1 (de) Neu substituierte Benzylamine und ihre Salze sowie Verfahren zu ihrer Herstellung
DE1951614B2 (de) Substituierte Benzylalkohol, deren physiologisch verträgliche Salze, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2402989B2 (de) Neue Benzylamine, sie enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
8128 New person/name/address of the agent

Representative=s name: LEDERER, F., DIPL.-CHEM. DR. MEYER-ROXLAU, R., DIP

8110 Request for examination paragraph 44
8128 New person/name/address of the agent

Representative=s name: LEDERER, F., DIPL.-CHEM. DR., PAT.-ANW., 8000 MUEN

D2 Grant after examination
8364 No opposition during term of opposition